Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYusuke SanoHTHiroyuki TakahashiMTMasahiro Takeuchi

Discussion

Loading...

Member takes

Overview

Interim analysis shows no PFS improvement with bortezomib plus daratumumab in transplant-ineligible multiple myeloma patients, highlighting adverse events.

Key Points

  • Progression-free survival remained unchanged after adding bortezomib to daratumumab maintenance therapy.
  • The interim analysis reported a median PFS rate of 80% with daratumumab alone compared to 72% with bortezomib.
  • Assessment included a randomized phase III study with transplant-ineligible patients undergoing maintenance therapy post-induction.
  • The findings may lead to reevaluation of treatment protocols considering tolerability and adverse event rates in arm B.

Cite This Study

Sano et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e093https://doi.org/10.1182/blood-2025-370
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial2025
  2. 2Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  3. 3Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study2025
  4. 4Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025
  5. 5Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025